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Abstract 
Background: Accumulating evidence has indicated that S100B may be involved in the pathophysiology of depres‑
sion. No published study has examined the effect of the antidepressant drug venlafaxine on S100B in animal models 
of depression. This study investigated S100B expression in the hippocampus and assessed the effect of venlafaxine on 
S100B mRNA level and protein expression in rats exposed to chronic unpredictable mild stress (CUMS).
Methods: Forty Sprague‑Dawley rats were randomly divided into four groups as control, 0, 5 and 10 mg venlafaxine 
groups. The venlafaxine groups were exposed to CUMS from day 2 to day 43. Venlafaxine 0, 5 and 10 mg/kg were 
then administered from day 23 to day 43. We performed behavioral assessments with weight change, open‑field and 
sucrose preference, and analyzed S100B protein expression and mRNA level in the hippocampus.
Results: The CUMS led to a decrease in body weight, locomotor activity and sucrose consumption, but venlafaxine 
treatment (10 mg) reversed these CUMS‑induced decreases Also, CUMS increased S100B protein expression and 
mRNA level in the hippocampus, but venlafaxine treatment (10 mg) significantly decreased S100B protein expres‑
sion and mRNA level, which were significantly lower than the other treatment groups, without significant difference 
between the 10 mg venlafaxine and the control groups.
Conclusions: Our findings showed that venlafaxine treatment (10 mg) may improve the depression‑like behaviors 
and decrease over‑expression of S100B protein and mRNA in the hippocampus in a rat model of depression.
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Background
Major depressive disorder (MDD) is one of the most 
common, serious mood disorders with a high recur-
rence rate, representing a major socio-economical bur-
den [1]. However, the pathogenic mechanisms are still 
unclear. Understanding the causes and neurobiologi-
cal basis of depression remains a challenge. Recently, it 
has been suggested that mood disorders are character-
ized by disease-specific glial pathology [2, 3]. Post mor-
tem studies showed reductions in glial cell density or 
glial cell numbers in prefrontal brain regions in patients 
with mood disorders [4], mainly displaying alterations of 
astrocytes and oligodendrocytes [5].
S100B is a glia-derived neurotrophic marker and an 
acidic and calcium-binding protein that is primarily pro-
duced by astrocytes and oligodendrocytes in the human 
brain [6]. Astrocytes are the main type of glial cells and 
are distributed throughout the nervous system. They 
have a role in the nutrition and protection of neurons 
and maintain brain and nervous system function. Under 
normal circumstances, high levels of S100B protein are 
mainly found in the cerebrospinal fluid (CSF), but low 
level of S100B in plasma and brain [7]. After brain injury, 
the activated microglia can secrete interleukin (IL) such 
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the activation and proliferation of glial cells, resulting 
in a large amount of S100B [8]. In the serum and CSF of 
patients with major depression, S100B protein has been 
shown to be increased compared to levels in healthy con-
trols [9, 10], although other studies did not demonstrate 
this difference in the CSF of MDD patients [11]. A post-
mortem study found that the density of S100B-immu-
nopositive astrocytes is decreased in the CA1 pyramidal 
layer of the hippocampus in patients with MDD [12]. In 
some longitudinal studies, it was reported that higher 
S100B levels were decreased after treatment with anti-
depressants [13]. A recent meta-analysis by Schroeter 
et al. [3] revealed that S100B serum levels were consist-
ently increased in acute major depressive or manic epi-
sodes, which was shown to be decreased after treatment 
with antidepressants, suggesting that S100B may be a 
biomarker for treatment outcomes in depression [14]. 
However, Ambrée et al. [15] reported low S100B levels in 
patients with depression, which predicted nonresponse 
to venlafaxine. Taken together, these studies suggest that 
the increased serum S100B levels may be involved in the 
pathophysiology of MDD and in pharmacological mecha-
nisms of antidepressants.
The hippocampus is an important brain region that 
can regulate emotions and cognition [16]. Some stud-
ies have reported neurochemical changes mainly in the 
hippocampus in patients with depression [17]. The anti-
depressant venlafaxine, which is widely used to treat 
patients with depression, has unique chemical charac-
teristics in inhibiting of 5-hydroxytryptamine (5-HT) 
and norepinephrine synaptosomal reuptake and increas-
ing brain 5-HT levels more than fluoxetine [18]. To our 
knowledge, no published studies have directly examined 
the alteration of S100B mRNA level and protein expres-
sion in the hippocampus of depression patients or animal 
models and the influence of venlafaxine on them. We 
hypothesized that the anti-depressant activity of ven-
lafaxine is associated with its effects on S100B mRNA 
level and protein expression in the hippocampus in a rat 




Forty male Sprague-Dawley rats (provided by the Exper-
imental Animal Center of Hebei Province, China), aged 
8–10  weeks and weight 240–280  g (SCXK2003-1-003) 
were housed under standard laboratory conditions and 
maintained on a 12-h light–dark cycle with free access 
to food and water. The animals and experimental proto-
cols were approved and supervised by the Institutional 
Animal Ethics Committee of the Xinxiang Medical 
University (with the ethical approval number 20090517) 
and followed the guidelines of the China National Sci-
ence Academy for the use and care of experimental 
animals.
Chronic unpredictable mild stress (CUMS) model
The CUMS procedure was modified based on the meth-
ods in previous reports [19]. All rats in the treated 
groups received a variety of different stimuli from day 2 
to day 43: (1) 45° cage tilt (for 24 h); (2) cold temperature 
swimming (water temperature 4 °C, 30 cm depth, every 
day for 5 min); (3) shaking (frequency: 1 per second, for 
10  min); (4) tail clamp (nipped the rat’s tail side of the 
body nearly 1/3 with large oval clamp for l min); (5) heat 
stress (rats placed in narrow-mouthed bottles at 45  °C 
for 5  min); (6) water deprivation (24  h); (7) food dep-
rivation (24 h); (8) noise stimulation (1500 Hz at 95 dB 
for l h/day; (9) 120 min limit behavior (the heads of rats 
were fixed in the end of a cylinder without affecting their 
breathing); (10) wet bedding (250 ml of water added to 
the cage with sawdust, 24  h). The rats received one of 
these ten stimulation styles each day and each stimulus 
was applied two or three times with a completely ran-
dom order. However, the same stimulus could not be 
used consecutively.
Drugs and drug treatment
Venlafaxine (Southwest Pharmaceutical Co., Ltd., 
Chengdu, China; Batch number: 080203) were dissolved 
in normal physiological saline. Rats were treated with 
venlafaxine at doses of 0, 5 or 10 mg/kg (1 ml/each rat) 
and were administered by oral gavage once a day for 
21  days. The dosages of venlafaxine used in this study 
were chosen based on previous reports by Chen et  al. 
[20] and Xing et al. [21].
The rats were randomly divided into four groups 
(n = 10/each group): (a) control group: rats were reared 
3–4/cage, and were neither exposed to CUMS nor treated 
with venlafaxine. (b) active groups: rats were housed 
individually in the cage and were exposed to CUMS from 
day 2 to day 43. Then they were administered with differ-
ent doses of venlafaxine (0, 5 or 10 mg/kg) from day 23 to 
day 43.
Behavioral assessment
Behavioral assessments were carried out on day 1, 22, 29, 
36 and 43, which were shown in Fig. 1. The tests on day 1 
and day 22 were used to examine whether the depression 
model was successful [19]. The tests on day 29, day 36 
and day 43 were to estimate whether the depression-like 
behaviors was reversed by different doses of venlafaxine 
at different time points.
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The body weight and the open‑field test
The body weight was measured before each the open-
field test and at day 1, 22, 29, 36 and 43, respectively 
to calculate the mean body weight change during the 
entirety of the experiment. The open-field test included 
the distance of horizontal motion, the number of verti-
cal motion, which was used to monitor the motor abil-
ity and explorative ability of the rats in an unfamiliar 
environment.
Following [19], rats were individually placed in a small 
100  cm ×  100  cm ×  40  cm Plexiglas cage and allowed 
30 s to accommodate to the observation cage. The behav-
ioral parameters of the open-field test were continuously 
measured for 5 min by three observers at the same time. 
In all the experiments, the scorers were blinded to ani-
mal treatment. Each rat was placed in the center of the 
open field; the distance of the horizontal motion was 
recorded by a data acquisition system (software of Smart 
2008, Germany). The number of vertical motion (rearing 
times) was recorded by the trained observers. The verti-
cal motion reflected explorative ability (curiosity) and 
horizontal motion referred to locomotor activity in an 
unfamiliar environment. Thus, the decrease of horizontal 
and vertical motion simulated the hypoactivity and anhe-
donia symptoms of depression.
Sucrose preference test
The sucrose preference test was performed as described 
previously [19, 22, 23], with minor modification. 
Decreased sucrose consumption was used to mimic the 
core symptoms of anhedonia in patients with depres-
sion. After deprivation of water and food for 12 h (21:00–
09:00  h), rats were free to access either of two bottles 
containing 1% sucrose solution or water. The positions 
of the two bottles were switched after 30  min. The rats 
were housed in individual cages. After 1 h, the volumes of 
consumed sucrose solution and water were recorded. The 
sucrose preference ratio (SPR) was calculated according 
to the following equation: SPR  =  sucrose intake (ml)/
sucrose intake (ml) + water intake (ml).
Immunohistochemistry
Experimental and control animals were sacrificed within 
12  h following the last behavior test [23]. All rats were 
deeply anesthetized with intraperitoneal injection of 
0.3  ml/100  g chloral hydrate. The brain was quickly 
removed, postfixed in 4% paraformaldehyde for 3–4  h, 
and kept overnight for 12 h. After dehydration and par-
affinization, serial 5-μm-thick coronal sections were cut. 
Sections were incubated for 10 min in 3% hydrogen per-
oxide to eliminate endogenous peroxidases, and then 
incubated with rabbit anti-S100B polyclonal antibody 
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
overnight at 4  °C. For negative controls, the antibody 
was replaced with normal goat serum. After removal of 
the primary antibody, the sections were all washed three 
times with PBS. Biotinylated goat anti-rabbit antibody 
(Bo Shi De, Wuhan, China) and streptavidin–biotin com-
plex (Bo Shi De, Wuhan, China) were then each applied 
for 20 min at 20–37  °C. Color for the peroxidase-linked 
antibody was developed with diaminobenzidine (DAB) 
for 5 min at room temperature. Finally, they were photo-
graphed under a light microscope [24].
In situ hybridization
The method of in  situ hybridization referred to the 
research of Bjørnebekk’s et al. [25]. Paraffin sections were 
fixed to glass slides and washed in water, and treated with 
3% hydrogen peroxide at room temperature for 10 min to 
inactivate endogenous peroxidase. After washing in dis-
tilled water three times, tissue sections were placed in 3% 
newly diluted pepsin with citric acid at room tempera-
ture for 30 min. After washing in PBS three times, each 
time for 5 min and in distilled water three times, sections 
were fixed in 1% paraformaldehyde/0.1 M PBS (pH 7.4) 
containing 1/1000 diethylpyrocarbonate at room temper-
ature for 10  min. After washing in distilled water three 
times, each time for 5  min, the sections were placed in 
20 µl pre-hybridization to solution at 38  °C for 2 h, and 
excess liquid was absorbed without washing. The sections 
were then placed in 20 µl hybridization solution (S100B 
oligonucleotide probe to target mRNA sequence was 
5′-TTCCA TCAGT ATTCA GGGAG AGAGG GTGAC 
AAGCA-3′), and the coverslip was placed on the glass 
slide and hybridized overnight at 38  °C. After removing 
the coverslip, the sections were washed twice for 1 min 
with 2× saline-sodium citrate (SSC) buffer, once for 
15  min with 0.5× SSC, and once for 15  min with 0.2× 
SSC at 37 °C. Sections were incubated orderly with block-
ing buffer at 37  °C for 30  min, biotinylated anti-mouse 
digoxin (Bo Shi De) for 1 h at 37 °C, streptavidin–biotin 
Fig. 1 The experimental process. CUMS: the procedure of chronic 
unpredictable stress from 2nd day to 43rd day; BT: behavioral test on 
the day 1, day 22, day 29, day 36 and day 43; 5 mg venlafaxine group: 
the animal received venlafaxine at a dose of 5 mg/day from day 22 to 
day 43; 10 mg venlafaxine group: the animal received venlafaxine at a 
dose of 10 mg/day from day 22 to day 43
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complex (Bo Shi De) for 20  min at 37  °C, biotin–per-
oxidase for 20  min at 37  °C, one drop DAB reagent for 
20  min at room temperature. After washing in running 
water, sections were dehydrated and made transparent. 
Finally, the coverslip was placed on the glass slide. Sec-
tions were visualized with a light microscope. In the 
negative control, S100B oligonucleotide probes were 
replaced by 0.1 M PBS (pH 7.4).
The analysis of the sections in immunohistochemistry 
and In situ hybridization
The sections were located in 3.3–3.8 mm distance from 
bregma and used Lecia Image collection and analysis sys-
tem (DM2000) to take the photographs of immunohis-
tochemistry and in  situ hybridization. The photographs 
were counted by means of Image pro-plus (6.0), which 
outcomes were adopt by the formula of Mean optical 
density (MOD)  =  Integral optical density (IOD)/Area. 
Four sections were selected to count each rat, and 10 rats 
were in each group.
Statistical analysis
To investigate the effects of different dose of venlafax-
ine on behavior tests and the change in the hippocam-
pal S100B protein expression and mRNA level, we used 
repeated-measures ANOVA test for interactions of treat-
ment grouping with changes in behavior tests and S100B 
expression and mRNA level, with baseline and post-
treatment values as the dependent measures (within-sub-
ject factors). Post hoc comparisons between groups were 
made using the Bonferronni or Tukey post hoc analysis. 
In addition, we compared the post-treatment values in 
the four groups using a univariate analysis of covariance 
(ANCOVA) with baseline value as covariate. S100B data 
was analyzed by one-way ANOVA followed by Bonfer-
ronni or Tukey post hoc analysis. Data were presented as 
mean ± SD. Differences at p < 0.05 level were considered 
to be significant. All statistical analyses were performed 
using SPSS, version 17.0 (Chicago, IL, USA).
Results
Body weight
Figure 2 presents the mean body weight on each testing 
occasion for the different groups. At baseline, there was 
no statistical difference between the four groups in body 
weight (F = 0.152, df = 3,36, p > 0.05). After 21 days of 
CUMS, all three treated groups showed significantly 
lower body weight than control group (0 mg venlafaxine: 
t = 13.2; 5 mg venlafaxine: t = 10.9; 10 mg venlafaxine: 
t = 12.794, all p < 0.001).
On day 29, there was a significant difference among the 
four groups (F = 93.2, df = 3,36, p < 0.001) and a signifi-
cant low body weight was found in the three treatment 
groups compared to control group (p < 0.01). On day 36, 
there was a significant difference among the four groups 
(F = 88.2, df = 3,36, p < 0.001) and high body weight was 
observed in the 10 mg venlafaxine group than that in the 
5 mg venlafaxine group (p < 0.001). On day 43, there was 
a significant difference among the four groups (F = 97.0, 
df = 3,36, p < 0.001) and the body weight in 10 mg ven-
lafaxine group was significantly greater than in the 5 mg 
venlafaxine group (p < 0.001); however, there was no sig-
nificant difference between the 10 mg venlafaxine group 
and the control group (p > 0.05) (Additional file 1).
The open‑field test
Figure 3 presents the open-field test results on each test-
ing occasion for the different groups. At baseline, there 
was no statistical difference between the four groups 
in the distance of horizontal motion and rearing times 
among the four groups (F =  0.248, df =  3,36, p  >  0.05; 
F = 1.282, df = 3,36, p > 0.05). After 21 days of CUMS, 
all three treated groups showed the decrease in distance 
of horizontal motion and rearing times compared to the 
control group (all p < 0.001).
On day 29, there was a significant difference in distance 
of horizontal motion, the rearing times among the four 
groups (F = 95.4, df = 3,36, p < 0.001; F = 25.0, df = 3,36, 
p < 0.001; respectively). Although the behaviors of open-
field test have still significant difference between the 
Fig. 2 The body weight at different time. The values are expressed as 
mean ± SD (n = 10/group). Compared with control group *p < 0.05, 
**p < 0.01. Compared with 0 mg venlafaxine group “#p < 0.05, 
##p < 0.01”. Compared with 10 mg venlafaxine group “&p < 0.05, 
&&p < 0.01”. On day 22, the body weight in control was higher than 
the other three groups (All p < 0.01). On day 29, there was still sig‑
nificant difference between the 0 mg venlafaxine and control group 
(p < 0.01); compared with the 0 mg venlafaxine group, the body 
weight was higher in the 10 mg venlafaxine. On day 36, there was 
still significant difference between the 0 mg venlafaxine and 10 mg 
venlafaxine group (p < 0.01). On day 43, the body weight was higher 
in the 10 mg venlafaxine compared with the 5 mg venlafaxine group
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three treated groups and control group (p < 0.01), higher 
times was found in the number of rearing in venlafax-
ine group(10 mg) than that in venlafaxine group (0 mg) 
(p < 0.05).
On day 36, there was a significant difference in distance 
of horizontal motion and rearing times among the four 
groups (F = 61.8, df = 3,36, p < 0.001; F = 21.7, df = 3,36, 
p < 0.001; F =  100.8, df =  3,36, p < 0.001, respectively) 
and the activities of the venlafaxine group (0  mg) were 
significantly lower than that of venlafaxine groups (5 or 
10 mg) (all p < 0.05). On day 43, there was a significant 
difference in distance of horizontal motion, the rear-
ing times among the four groups (F  =  51.9, df  =  3,36, 
p < 0.001; F = 45.9, df = 3,36, p < 0.001) and significant 
increase in the open-field tests was observed in venlafax-
ine group (10 mg) compared to venlafaxine group (5 mg) 
(all p  <  0.05), but no significant differences in all open-
field tests were observed between 10  mg venlafaxine 
group and control group (all p > 0.05) (Additional file 2).
Sucrose preference test
Figure  4 presents the sucrose preference test results on 
each testing occasion for the different groups. At baseline, 
there was no statistical difference in sucrose preference 
test among the four groups (F = 0.192, df = 3,36, p > 0.05). 
After 21  days of CUMS, all three treated groups showed 
significantly lower sucrose preference than control group 
(0 mg venlafaxine t = 13.104, p < 0.001; 5 mg venlafaxine 
t = 9.510, p < 0.001; 10 mg venlafaxine t = 9.955, p < 0.001).
On day 29, there was a significant difference among the 
four groups (F = 29.2, df = 3,36, p < 0.001) and the con-
trol group still showed greater sucrose preference than 
the treated groups (all p < 0.01). On day 36, there was a 
significant difference among the four groups (F =  32.9, 
df = 3,36, p < 0.001) and both the 0 and 5 mg venlafax-
ine groups had lower sucrose preference than the 10 mg 
venlafaxine group (both p < 0.001). On day 43, there was 
a significant difference among the four groups (F = 22.8, 
df  =  3,36, p  <  0.001) and significant difference was 
observed between 10 versus 5  mg venlafaxine groups Fig. 3 Behaviors of the open‑field test at different time. The values are expressed as mean ± SD (n = 10/group). Compared with control 
group “*p < 0.05, **p < 0.01”. Compared with 0 mg venlafaxine group 
“#p < 0.05, ##p < 0.01”. Compared with 10 mg venlafaxine group 
“&p < 0.05, &&p < 0.01”. a Distance of horizontal motion; b rearing 
times. On day 22, there were significant differences among the 
control group and three treated groups in distance of horizontal 
motion, and rearing times (all p < 0.01). On day 29, there was still sig‑
nificant difference between the 0 mg venlafaxine and control group 
(p < 0.01). On day 36, there was still significant difference between 
the 0 mg venlafaxine and 10 mg venlafaxine group (p < 0.01). On day 
43, the distance of horizontal motion and number of vertical motion 
was higher in the 10 mg venlafaxine compared with the 5 mg venla‑
faxine group (p < 0.01)
Fig. 4 The sucrose preference test at different time. The values are 
expressed as mean ± SD (n = 10/group). Compared with control 
group “*p < 0.05, **p < 0.01”. Compared with 0 mg venlafaxine group 
“#p < 0.05, ##p < 0.01”. Compared with 10 mg venlafaxine group 
“&p < 0.05, &&p < 0.01”. On day 22, the sucrose preference in control 
was higher than the other three groups (all p < 0.01). On day 29, there 
was still significant difference between the 0 mg venlafaxine and con‑
trol group (p < 0.01); compared with the 0 mg venlafaxine group, the 
sucrose preference was higher in the 10 mg venlafaxine (p < 0.01). On 
day 36, there was still significant difference between the 0 mg venla‑
faxine and 10 mg venlafaxine group (p < 0.01). On day 43, the sucrose 
preference was higher in the 10 mg venlafaxine compared with the 
5 mg venlafaxine group (p < 0.01)
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(all p < 0.05), but no significant difference was observed 
between 10  mg venlafaxine group and control group 
(p > 0.05) (Additional file 3).
Immunohistochemistry and in situ hybridization
Significant difference in S100B protein expression 
was observed in the four groups (F  =  31.4, df  =  3,36, 
p < 0.001). S100B protein expression in saline group was 
significantly higher than in the other three groups (all 
p  <  0.05); however, no significant difference was noted 
between the control and 10  mg venlafaxine groups 
(p > 0.05). Further, S100B protein expression was signifi-
cantly greater in the 5 mg venlafaxine group than in the 
control and 10 mg venlafaxine groups (p < 0.001; p < 0.01, 
respectively) (Figs.  5, 6). In addition, significant differ-
ences in S100B mRNA expression were observed among 
the four groups (F = 23.7, df = 3,36, p < 0.001), and the 
control group showed greater S100B mRNA expression 
than the other three groups (all p < 0.05). After 21 days 
of venlafaxine treatment, S100B mRNA expression was 
significantly greater in the 5 mg venlafaxine group than 
in the control and 10 mg venlafaxine groups (p < 0.001; 
p < 0.01, respectively); however, no significant difference 
was noted between the 10  mg venlafaxine and control 
groups (p > 0.05) (Figs. 7, 8) (Additional file 4).
Discussion
The CUMS-induced behavioral changes may simulate 
depression-like behaviors in individuals with depression, 
which is considered as one of the classical models [26]. 
In our present study, following three weeks of chronic 
stress, decreases in distance of horizontal motion and the 
rearing times in an open-field suggested lowered motor 
ability and explorative ability. Body weight and sucrose 
consumption, similar to the symptoms of psychomotor 
inhibition, anhedonia, and appetite decreases in depres-
sion [1], were decreased in the treated groups compared 
to the control group. Taken together, CUMS-induced 
behavioral changes in our present study paralleled the 
symptoms of depression in humans.
The present results in this animal model of depression 
confirm that both 5 and 10  mg venlafaxine administra-
tion improved the depression-like behaviors at day 36 
and day 43 after 2- and 3-week treatments. Moreover, 
venlafaxine treatment (10 mg) produced anti-depression 
effects better than 5  mg venlafaxine treatment at both 
time points. Interestingly, the depression-like behaviors 
in rats were reversed fully to normal levels by 21-day 
treatment of 10 mg venlafaxine, suggesting that high dose 
of venlafaxine may produce better therapeutic effects 
than low dose.
A further finding of our present study is that S100B 
expression and mRNA levels were markedly increased 
in the hippocampus of the CUMS model of depression 
suggesting that the depression-like behaviors induced 
by CUMS might be associated with the elevated S100B 
mRNA level and protein expression in the hippocam-
pus. Our results were consistent with two previous 
studies by Gosselin et al. [27], who reported an increase 
in the intensity of S100b immunoreactivity in prefron-
tal cortex region, the basolateral amygdala as well as in 
the hippocampus, and by Ye et  al. [28], who reported 
that CUMS produced increased S100b expression in rat 
hippocampus.
As mentioned previously, S100B is considered as a 
potential biomarker of structural brain damage and dis-
ease activity [29]. S100B displays neuroprotective or neu-
rodegenerative effects depending on its concentration. 
At nanomolar concentrations, S100B has been shown to 
have neurotrophic effects [30], whilst at elevated con-
centrations (micromolar) is neurotoxic participating in a 
cascade of events leading to cell death or apoptosis [31]. 
Numerous studies have shown that S100B is altered in 
both serum and CSF of patients with mood disorders [3, 
32]. Increased S100B levels have been reported in CSF in 
drug-free mild to moderate depressive patients compared 
with euthymic patients [33]. Moreover, S100B levels were 
decreased following successful treatment with antide-
pressant [34]. The most recent meta-analysis including a 
very high number of subjects has shown that fluctuations 
in serum levels of S100B seem to be state markers for 
major depression [35]. Furthermore, S100B serves as a 
biochemical predictor of behavioral responses to chronic 
Fig. 5 Mean optical density for S100B protein in the hippocampus. 
The values are expressed as mean ± SD (n = 10/group). Compared 
with control group “*p < 0.05, **p < 0.01”. Compared with 0 mg venla‑
faxine group “#p < 0.05, ##p < 0.01”. Compared with 10 mg venlafaxine 
group “&p < 0.05, &&p < 0.01”. The S100B protein in 0 mg venlafaxine 
was higher than the other three groups (all p < 0.01). There was sig‑
nificant difference between the 10 mg venlafaxine and control group 
(p < 0.01); compared with the 5 mg venlafaxine group, S100B protein 
was lower in the 10 mg venlafaxine (p < 0.01)
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fluoxetine treatment [36]. Hence, it has been proposed 
that S100B serum and CSF levels may represent a suitable 
surrogate marker of glial damage or dysfunction in mood 
disorders [3, 8]. However, a recent postmortem analysis 
showed that the numerical density of S100B-immunop-
ositive astrocytes was bilaterally decreased in the CA1 
pyramidal layer of the hippocampus in MDD and bipo-
lar disorder (BD) patients compared to controls [12]. The 
authors assume that reduced glial S100B-immunostain-
ing in the hippocampus of MDD and BD patients is 
rather caused by an increased release of S100B from glial 
cells than by reduced cellular S100B expression, because 
of the observed increase in levels of S100B in the periph-
eral blood and CSF of MDD and BD patients [8, 10, 14]. 
Taken together, our finding of increased S100B expres-
sion and mRNA levels in the hippocampus of The CUMS 
model of depression suggests that that S100B overexpres-
sion may be a significant marker related to the patho-
physiology of the depression.
Interestingly, we found that high dose of venlafaxine 
at 10 mg not only reversed the CUMS induced behavio-
ral changes in rats, but also reduced increased levels of 
S100B mRNA level and protein expression. We speculate 
Fig. 6 S100B protein pictures in the immunohistochemistry. a Control group; b 0 mg venlafaxine group; c 5 mg venlafaxine group; d 10 mg venla‑
faxine group. The amplification factor of each picture was ×200; the scale bars of every picture were 50 μm; →: positive staining
Fig. 7 Mean optical density for S100B mRNA in the hippocampus. 
The values are expressed as mean ± SD (n = 10/group). Compared 
with control group “*p < 0.05, **p < 0.01”. Compared with 0 mg venla‑
faxine group “#p < 0.05, ##p < 0.01”. Compared with 10 mg venlafaxine 
group “&p < 0.05, &&p < 0.01”. The S100B mRNA level in 0 mg venla‑
faxine was higher than the other three groups (all p < 0.01). The sig‑
nificant difference had been found between the 10 mg venlafaxine 
and 5 m venlafaxine (p < 0.01); compared with the 0 mg venlafaxine 
group, there was no significance in the 10 mg venlafaxine (p < 0.01)
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that venlafaxine may ameliorate the depression-like 
behaviors by influencing the expression of S100B in the 
hippocampus.
It was reported that S100B protein stimulated secretion 
of pro-inflammatory cytokines including IL-1β, IL-6, IL-8 
and tumor necrosis factor (TNF)-α through activated glial 
cells [37, 38], acting as proinflammatory molecule [39]. 
Therefore, the increased S100B expression in our model 
of depression may originate from the activated glial cells 
of the hippocampus and elevate the release of pro-inflam-
matory cytokines. Recent studies reported that vatairea 
macrocarpa lectin (VML) caused an enhancement of 
S100B levels, trigger neuroinflammatory response in 
mouse hippocampus and exhibited a depressive-like 
activity [40], suggesting close relationships between the 
increased S100B and neuroinflammatory markers in the 
hippocampus and depressive-like behaviors. Some stud-
ies have indicated that higher blood levels of pro-inflam-
matory cytokines TNF-α and IL-6 in drug-free patients 
with depression [41, 42]. Moreover, the pro-inflamma-
tory cytokines levels were normalized once antidepres-
sant treatment was administered [43]. In addition, it has 
been demonstrated that the selective serotonin reup-
take inhibitors (SSRIs) and serotonin–norepinephrine 
reuptake inhibitors (SNRIs) exerted anti-inflammatory 
effects in  vivo [44, 45]. Furthermore, Ohgi et  al. [46] 
examined the effects of SSRIs and SNRIs on lipopoly-
saccharide-induced depression in mice, and found that 
the two types of antidepressants have anti-inflammatory 
effects by decreasing TNF-α and increasing IL-10 levels 
in serum. Also, it has been reported that venlafaxine has 
an anti-inflammatory effect by the way of suppression 
on interferon-γ/IL-10 production ratio. The increased 
hippocampal levels of pro-inflammatory cytokines have 
been found in the CUMS model of depression, and the 
improvement of CUMS-induced depression-like behav-
iors are associated with a reduction of pro-inflammatory 
cytokines in the rat hippocampus [47, 48]. In addition, the 
astrocytes have been damaged and their immunoreactiv-
ity decrease in the hippocampus of rats exposed to the 
CUMS [28, 49]. Taken together, we speculate that chronic 
stress may lead to damage of astrocytes and the hip-
pocampus, causing increases in S100B, which in turn may 
result in pro-inflammatory cytokines and depression-like 
symptoms in the CUMS model of depression. After treat-
ment with venlafaxine, the increased expression of S100B 
mRNA and protein levels was decreased and the release of 
proinflammatory cytokine declined in the hippocampus, 
Fig. 8 S100B mRNA pictures in situ hybridization. a Control group; b 0 mg venlafaxine group; c 5 mg venlafaxine group; d 10 mg venlafaxine 
group. The amplification factor of each picture was ×200; the scale bars of every picture were 50 μm; →: positive staining
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leading to improvements in the depression-like behaviors. 
However, the mechanisms underlying venlafaxine effects 
on depression-like behaviors deserve future investigation.
Several limitations of the study should be noted here. 
First, our study was focused on a single molecular inves-
tigation of S100B; however, numerous neurotrophic fac-
tors are involved in brain activities. It has been known 
that there is an interrelationship between different neu-
rotrophins, such as interactions between BDNF and 
S100B [50]. Second, all the drugs were administered by 
oral gavage, a very invasive route of administration and 
source of stress for the animals. Consequently, the oral 
gavage could be a reason for weight loss observed in the 
treated rats. A group of naive animals should have been 
included in the experimental protocol to assess the effect 
of the stress of the gavage procedure on the evaluated 
parameters.
In summary, we found that chronic stress led to 
depression-like behaviors and increased S100B expres-
sion and mRNA levels in the hippocampus, suggesting 
that increased S100B may be relevant to the pathology 
of depression. Venlafaxine treatment (10  mg) improved 
these chronic stress induced depression-like behaviors 
and decreased the elevated S100B levels to the normal 
range. We speculate that venlafaxine may ameliorate the 
depression-like behaviors by influencing the expression 
of S100B in the hippocampus, which may work through 
its anti-inflammatory effect. However, this is only our 
speculation. The inter-relationships between increased 
S100B levels and pro-inflammatory cytokines in the hip-
pocampus and depression deserves further investigation, 
and especially whether the anti-inflammatory effects of 
venlafaxine may contribute to its effects on the reduction 
of S100B level and reversal of the depression-like behav-
iors warrant further studies.
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